Sandoz has settled US patent-litigation proceedings with Bausch Health’s Salix affiliate over the generics company’s application for a rival to the originator’s Xifaxan (rifaximin) 550mg tablets, obtaining a guaranteed market entry date that matches that afforded previously to Teva’s Actavis.
Sandoz Matches Teva On US Rifaximin Launch Date
Company Had Been Sued In October Last Year
Sandoz has joined a fellow major generics player, Teva’s Actavis, in settling itself out of litigation with Bausch Health over Xifaxan 550mg tablets in the US. The two settlement agreements contain key similarities and differences.
